Lauren L Jantzie1, Kathryn G Todd. 1. Neurochemical Research Unit, Department of Psychiatry, University of Alberta, Edmonton, Alta., Canada.
Abstract
BACKGROUND: Neonatal hypoxia-ischemia (HI) is a major cause of perinatal brain injury and is associated with a spectrum of neuropsychiatric disorders. Although very few treatment options are currently available, doxycycline (DOXY) has been reported to be neuroprotective in neontatal HI. Our objective was to investigate the effects of DOXY on neonatal brain development in normal and HI rat pups. We hypothesized that DOXY would inhibit microglial activation but that developmentally important processes, including cytogenesis and trophic responses, would not be impaired. METHODS: To investigate the putative neurodevelopmental consequences of DOXY administration in a clinically relevant animal model of HI, we performed a time-course analysis such that postnatal rat pups received DOXY (10mg/kg) or vehicle immediately before HI (n >or= 6). We then assessed cytogenesis, proinflammatory cytokines, brain-derived neurotrophic factor (BDNF) and matrix metalloproteinases regionally and longitudinally. RESULTS: We found that DOXY significantly inhibits neuroinflammation in the frontal cortex, striatum and hippocampus; decreases interleukin-1Beta (IL-1Beta) and tumour necrosis factor-alpha (TNF-alpha); and augments BDNF following HI. In addition, DOXY-treated pups have significantly fewer 2-bromo-5-deoxyuridine (BrdU)-positive cells in the subventricular zone 6 hours post-HI. However, DOXY does not persistently affect cytogenesis in the subventricular zone or dentate gyrus up to 7 days post-HI. The BrdU-positive cells not expressing markers for mature neurons colabel with nestin, an intermediate filament protein typical of neuronal precursors. LIMITATIONS: Our study investigates "acute" neurodevelopment over the first 7 days of life after HI injury. Further long-term investigations into adulthood are underway. CONCLUSION: Taken together, our results suggest the putative clinical potential of DOXY in the management of neonatal cerebral HI injury.
BACKGROUND:Neonatal hypoxia-ischemia (HI) is a major cause of perinatal brain injury and is associated with a spectrum of neuropsychiatric disorders. Although very few treatment options are currently available, doxycycline (DOXY) has been reported to be neuroprotective in neontatal HI. Our objective was to investigate the effects of DOXY on neonatal brain development in normal and HI rat pups. We hypothesized that DOXY would inhibit microglial activation but that developmentally important processes, including cytogenesis and trophic responses, would not be impaired. METHODS: To investigate the putative neurodevelopmental consequences of DOXY administration in a clinically relevant animal model of HI, we performed a time-course analysis such that postnatal rat pups received DOXY (10mg/kg) or vehicle immediately before HI (n >or= 6). We then assessed cytogenesis, proinflammatory cytokines, brain-derived neurotrophic factor (BDNF) and matrix metalloproteinases regionally and longitudinally. RESULTS: We found that DOXY significantly inhibits neuroinflammation in the frontal cortex, striatum and hippocampus; decreases interleukin-1Beta (IL-1Beta) and tumour necrosis factor-alpha (TNF-alpha); and augments BDNF following HI. In addition, DOXY-treated pups have significantly fewer 2-bromo-5-deoxyuridine (BrdU)-positive cells in the subventricular zone 6 hours post-HI. However, DOXY does not persistently affect cytogenesis in the subventricular zone or dentate gyrus up to 7 days post-HI. The BrdU-positive cells not expressing markers for mature neurons colabel with nestin, an intermediate filament protein typical of neuronal precursors. LIMITATIONS: Our study investigates "acute" neurodevelopment over the first 7 days of life after HI injury. Further long-term investigations into adulthood are underway. CONCLUSION: Taken together, our results suggest the putative clinical potential of DOXY in the management of neonatal cerebral HI injury.
Authors: Daniela Lind; Sebastian Franken; Joachim Kappler; Jakob Jankowski; Karl Schilling Journal: J Neurosci Res Date: 2005-02-01 Impact factor: 4.164
Authors: Chia-Yi Kuan; Aryn J Schloemer; Aigang Lu; Kevin A Burns; Wei-Lan Weng; Michael T Williams; Kenneth I Strauss; Charles V Vorhees; Richard A Flavell; Roger J Davis; Frank R Sharp; Pasko Rakic Journal: J Neurosci Date: 2004-11-24 Impact factor: 6.167
Authors: P E Batchelor; G T Liberatore; J Y Wong; M J Porritt; F Frerichs; G A Donnan; D W Howells Journal: J Neurosci Date: 1999-03-01 Impact factor: 6.167
Authors: John Bartley; Thomas Soltau; Hereward Wimborne; Sunjun Kim; Angeline Martin-Studdard; David Hess; William Hill; Jennifer Waller; James Carroll Journal: BMC Neurosci Date: 2005-03-02 Impact factor: 3.288
Authors: Hector R Galván-Salazar; Alejandro D Soriano-Hernández; Daniel A Montes-Galindo; Gabriel Ceja Espíritu; José Guzman-Esquivel; Iram P Rodríguez-Sánchez; Oscar A Newton-Sánchez; Margarita L Martinez-Fierro; Xóchitl G Briseño Gómez; Augusto Rojas-Martínez; Iván Delgado-Enciso Journal: Mol Clin Oncol Date: 2016-09-08
Authors: Ivan Delgado-Enciso; Alejandro García-Rivera; M Violeta M Madrigal-Pérez; Alejandrina Rodriguez-Hernandez; Agustin Lugo-Radillo; Hector R Galvan-Salazar; Alejandro D Soriano-Hernández; Fernando Gómez-Tapia; Rafael Martinez-Martinez; Laura L Valdez-Velazquez; Oscar A Newton-Sanchez; Rafael Gonzalez-Alvarez; Iram P Rodriguez-Sanchez; Valery Melnikov; Agustin Lara-Esqueda; Jose Guzman-Esquivel Journal: Int Urol Nephrol Date: 2013-11-28 Impact factor: 2.370